Theranostics of prostate cancer using Lu-177-labeled PSMA small molecule for peptide radioligand therapy (PRLT)

Baum R. P.; Kulkarni H. R.; Wester H. -J.

首页> 外文期刊>The Journal of Nuclear Medicine >Theranostics of prostate cancer using Lu-177-labeled PSMA small molecule for peptide radioligand therapy (PRLT)

【24h】

Theranostics of prostate cancer using Lu-177-labeled PSMA small molecule for peptide radioligand therapy (PRLT)

机译：使用Lu-177标记的PSMA小分子进行肽放射配体治疗（PRLT）的前列腺癌治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of Nuclear Medicine》 |2015年第2期|共2页
作者
Baum R. P.; Kulkarni H. R.; Wester H. -J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. Theranostics of prostate cancer using Lu-177-labeled PSMA small molecule for peptide radioligand therapy (PRLT) [J] . Baum R. P., Kulkarni H. R., Wester H. -J. The Journal of Nuclear Medicine . 2015,第Suppla2期

机译：使用Lu-177标记的PSMA小分子进行肽放射配体治疗（PRLT）的前列腺癌治疗
2. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with Lu-177-Labeled PSMA-617 [J] . Kratochwil Clemens, Giesel Frederik L., Stefanova Melsa, The Journal of Nuclear Medicine . 2016,第8期

机译：带有Lu-177标签的PSMA-617的PSMA靶向放射性核素治疗转移性去势抵抗性前列腺癌
3. Examining Absorbed Doses of Indigenously Developed Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy [J] . Kamaldeep, Wanage Gaurav, Sahu Sudeep Kumar, Cancer biotherapy and radiopharmaceuticals . 2021,第3期

机译：在基线和肽受体放射性和治疗期间检查在基线和肽受体的转移阉割前列腺癌患者中的吸收剂量的抗性阉割抗性前列腺癌患者
4. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers [C] . Hunho Jo, Changill Ban Annual NSTI nanotechnology conference and expo . 2013

机译：基于双适体的阿霉素对PSMA（+）和PSMA（-）前列腺癌的传递载体
5. Development of PSMA Targeted Polymer Nanoparticles to Treat Prostate Cancer by Boron Neutron Capture Therapy Directed against PSMA [D] . Dhrona, Suchi. 2021

机译：PSMA靶向聚合物纳米粒子的研制通过针对PSMA的硼中子捕获治疗治疗前列腺癌
6. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy [O] . Robert Seifert, Konstantin Seitzer, Ken Herrmann, 2020

机译：接受177Lu-PSMA-617放射配体疗法的晚期前列腺癌患者PSMA表达和结局分析
7. PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy [O] . Liam Widjaja, Rudolf A. Werner, Tobias L. Ross, 2021

机译：PSMA表达预测177LU-PSMA-617放射性配体疗法的转移性阉割抗性前列腺癌患者的早期生化反应
8. Enzymatic Activation of Peptide Prodrugs by Prostate-Specific Membrane Antigen (PSMA) as Targeted Therapy for Prostate Cancer [R] . Denmeade, S. R. 2005

机译：前列腺特异性膜抗原（psma）作为靶向治疗前列腺癌对肽前药的酶促活化

Theranostics of prostate cancer using Lu-177-labeled PSMA small molecule for peptide radioligand therapy (PRLT)

著录项

相似文献

相关主题

期刊订阅